Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Breast Neoplasms 273Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 181Neoplasms 174Lung Neoplasms 137Multiple Myeloma 136Neoplasm Metastasis 101Colorectal Neoplasms 100Melanoma 87Ovarian Neoplasms 80Leukemia, Myeloid, Acute 74Pancreatic Neoplasms 73Lymphoma 69Carcinoma, Renal Cell 65Leukemia, Lymphocytic, Chronic, B-Cell 64Brain Neoplasms 63Lymphoma, Non-Hodgkin 62Squamous Cell Carcinoma of Head and Neck 61Recurrence 56Urinary Bladder Neoplasms 55Hematologic Neoplasms 55Carcinoma, Hepatocellular 54Head and Neck Neoplasms 53Triple Negative Breast Neoplasms 51Lymphoma, Follicular 48Glioblastoma 48Endometrial Neoplasms 47Uterine Cervical Neoplasms 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Sarcoma 44

Interventions

nilotinib 2asciminib 2bosutinib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Philadelphia Chromosome × 90 days × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡